title: Cardiovascular toxicity of tyrosine kinase inhibitors.
abstract: BACKGROUND
  Small-molecule tyrosine kinase inhibitors (TKIs) have revolutionized the management of many malignancies. However, they also have been shown to be associated with a certain degree of cardiovascular side effects that are often reversible.
  
  
  METHODS
  As the number of new TKIs continues to grow, it is expected that clinicians will be facing the challenge of early detection and 10 management of these side effects while balancing the risk-benefit ratios of continuing with life-saving cancer therapy medications. This review will present the current knowledge related to incidence and proposed mechanisms of cardiovascular side effects of TKIs and also discuss treatment recommendations when available
  
  
  CONCLUSIONS
  We will present and discuss available data and suggest recommendations related to patient monitoring and early identification of TKIs related cardiovascular toxities.
authors.affiliation: University of Texas/MD Anderson Cancer Center, Cardiology, 1515 Holcombe Boulevard, Unit 1451, Houston, TX, 77030-4009, USA. emouhayar@mdanderson.org
authors.forename: Elie
authors.initials: E
authors.lastname: Mouhayar
authors.forename: Jean-Bernard
authors.initials: JB
authors.lastname: Durand
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002319:Cardiovascular System / Q000187:drug effects*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases